DAFNA Capital Management LLC - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 77 filers reported holding PROQR THRAPEUTICS N V in Q4 2021. The put-call ratio across all filers is 2.49 and the average weighting 0.2%.

Quarter-by-quarter ownership
DAFNA Capital Management LLC ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q3 2023$1,222,757
-19.8%
940,5820.0%0.38%
-8.9%
Q2 2023$1,523,743
-23.9%
940,5820.0%0.42%
-30.6%
Q1 2023$2,003,440
+314.8%
940,582
+44.8%
0.60%
+362.3%
Q3 2022$483,000
-29.5%
649,383
+659.7%
0.13%
-24.4%
Q4 2021$685,000
-72.4%
85,476
-71.2%
0.17%
-73.9%
Q3 2021$2,481,000
-64.3%
296,383
-71.3%
0.66%
-54.8%
Q2 2021$6,955,000
-4.3%
1,031,880
-6.2%
1.46%
-15.7%
Q1 2021$7,271,000
+39.9%
1,100,000
-11.1%
1.72%
+11.6%
Q4 2020$5,197,000
-12.3%
1,237,4000.0%1.55%
-19.8%
Q3 2020$5,927,000
-21.2%
1,237,4000.0%1.93%
-11.2%
Q2 2020$7,523,000
+10.7%
1,237,4000.0%2.17%
-23.4%
Q1 2020$6,793,000
-38.5%
1,237,400
+11.1%
2.84%
-25.2%
Q4 2019$11,040,000
+633.1%
1,114,000
+326.0%
3.79%
+569.4%
Q3 2019$1,506,000
-36.7%
261,5210.0%0.57%
-36.8%
Q2 2019$2,380,000
-34.4%
261,5210.0%0.90%
-42.8%
Q1 2019$3,627,000
-15.7%
261,521
-4.0%
1.56%
-26.8%
Q4 2018$4,300,000
-14.6%
272,474
+4.7%
2.14%
+3.3%
Q3 2018$5,038,000
+302.7%
260,336
+51.9%
2.07%
+253.1%
Q2 2018$1,251,000
+76.2%
171,351
-25.7%
0.59%
+69.9%
Q1 2018$710,000
-4.6%
230,7700.0%0.34%
-14.0%
Q4 2017$744,000230,7700.40%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q4 2021
NameSharesValueWeighting ↓
DAFNA Capital Management LLC 1,237,400$5,197,0001.55%
Prosight Management, LP 255,000$1,071,0000.50%
RTW INVESTMENTS, LP 5,009,768$21,041,0000.35%
Kerrisdale Advisers, LLC 453,182$1,903,0000.15%
Artal Group S.A. 1,196,218$5,024,0000.11%
COWEN AND COMPANY, LLC 285,696$1,200,0000.11%
Golden Green, Inc. 16,999$71,0000.07%
APOGEM CAPITAL LLC 15,855$67,0000.04%
ADAGE CAPITAL PARTNERS GP, L.L.C. 4,550,062$19,110,0000.04%
ALTRINSIC GLOBAL ADVISORS LLC 241,360$1,014,0000.03%
View complete list of PROQR THRAPEUTICS N V shareholders